(Q36119978)

12 August 2017

1 reference

title

Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma (English)

1 reference

12 August 2017

Alan P Venook

1

1 reference

PubMed ID

15880563

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

12 August 2017

1 reference

12 August 2017

103

1 reference

12 August 2017

12

1 reference

12 August 2017

2435-2446

1 reference

The effects of intracolonic EGF on mucosal growth and experimental carcinogenesis

12 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

Uncommon presentations of Hodgkin's disease. Case 3. Hodgkin's disease: rectal presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

21 January 2018

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Therapeutic opportunities from tumour biology in metastatic colon cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Progress in colorectal cancer chemotherapy: how far have we come, how far to go?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Therapeutics targeting signal transduction for patients with colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.21123

1 reference

7 January 2021

Structure, function and transforming potential of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Signaling through the epidermal growth factor receptor during the development of malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Growth factors and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Proliferation of human colon cancer cells: role of epidermal growth factor and transforming growth factor alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Improving the efficacy of antibody-based cancer therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Monoclonal antibodies as therapeutic agents for cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Monoclonal antibodies as therapeutics in oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Human antibody effector function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Nuclear targeting of Bax during apoptosis in human colorectal cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Epidermal growth factor receptor expression and measurement in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Clinical experience with CD64-directed immunotherapy. An overview

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Complications of malignancy: case 1. Systemic tumor embolism from lung cancer at presentation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Somatic mutations of EGFR in colorectal cancers and glioblastomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Tyrosine Kinase Inhibitors. 13. Structure−Activity Relationships for Soluble 7-Substituted 4-[(3-Bromophenyl)amino]pyrido[4,3-d]pyrimidines Designed as Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Epidermal growth factor receptor as a therapeutic target in colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21123

7 January 2021

Identifiers

DOI

10.1002/CNCR.21123

1 reference

release_ytju4ayglvflnkrpdao55owmau

12 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ytju4ayglvflnkrpdao55owmau

24 November 2022

mapped directly with Wikidata item

PubMed ID

15880563

1 reference

PubMed ID

15880563